Research Insight
PANEL: FLU SPRAY BETTER THAN SHOTS FOR YOUNG KIDS
When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot in the arm for young children. The advisory panel voted Wednesday to advise doctors that FluMist...
Research Insight
Reducing readmissions: Top strategy for improving quality, lowering costs
Dr. Fortuna says payers should consider expand their perspectives on improving the healthcare system by adopting the use of the tools, methodologies and quality improvement professionals (engineers) that other industries have with great success as recommended in the May...
Research Insight
Capravirine – Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is a Non-Nuclesoide Reverse Transcriptase Inhibitor (NNRTI) that was under development for the treatment of patients infected with the Human Immunodeficiency Virus (HIV). It was indicated for patients with HIV/AIDS who...
Research Insight
Recycled blood is better than donated blood for transfusions, Hopkins study finds
We recycle a lot of things — paper, plastic, metal, blood. Yes, blood. During some surgeries, operating room personnel try to capture as much blood as possible and return the red blood cells to your system, instead of, or...
Research Insight
Abraxane for the Treatment of Late-Stage Pancreatic Cancer, United States of America
Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer. The drug was originally developed by Abraxis BioScience, which was acquired by Celgene Corporation in October 2010. Celgene...
Research Insight
Zonegran (Zonisamide) for the Treatment of Epilepsy, Switzerland
Zonegran (Zonisamide) is an anti-epileptic drug indicated for the treatment of partial seizures in adults with epilepsy with or without secondary generalisation. The drug was originally discovered and developed by Dainippon Pharmaceutical (now Dainippon Sumitomo Pharma)....
Research Insight
Cetilistat – Investigational Drug for Obesity, Japan
Developed by Alizyme, a specialist biopharmaceutical company in collaboration with Takeda Pharmaceutical, cetilistat (ATL-962) is an experimental treatment for obesity. Cetilistat restricts pancreatic lipases and acts as an agent to treat obesity and related diabetes or dyslipidemia. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















